Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer

Prof. Francois-Clement Bidard from Institut Curie in Paris and Dr. Kevin Kalinsky from Winship Cancer Institute dive into enhancing treatments for HR-positive, HER2-negative metastatic breast cancer. They explore the role of CDK inhibitors in older patients and the impact of ESR1 mutations on treatment resistance. The discussion highlights the evolution of clinical trials, personalized therapies, and innovative strategies aimed at improving long-term patient outcomes. Together, they emphasize the importance of patient involvement and genetic insights in shaping treatment decisions.